Novo Nordisk Future Growth

Future criteria checks 4/6

Novo Nordisk is forecast to grow earnings and revenue by 13.3% and 13.8% per annum respectively. EPS is expected to grow by 15% per annum. Return on equity is forecast to be 85.6% in 3 years.

Key information

13.3%

Earnings growth rate

15.0%

EPS growth rate

Pharmaceuticals earnings growth	14.1%
Revenue growth rate	13.8%
Future return on equity	85.6%
Analyst coverage	Good
Last updated	14 Jun 2024

Recent future growth updates

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04

Recent updates

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jun 09

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

May 09

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04

Earnings and Revenue Growth Forecasts

CPSE:NOVO B - Analysts future estimates and past financials data (DKK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	405,479	147,821	117,638	165,880	22
12/31/2025	351,918	127,775	95,945	145,293	26
12/31/2024	291,350	104,723	67,963	123,540	26
3/31/2024	244,243	89,276	50,304	93,408	N/A
12/31/2023	232,261	83,683	70,012	108,908	N/A
9/30/2023	214,490	75,312	77,825	106,458	N/A
6/30/2023	201,325	67,239	67,497	89,731	N/A
3/31/2023	188,290	61,129	67,341	85,115	N/A
12/31/2022	176,954	55,525	64,134	78,887	N/A
9/30/2022	167,195	52,825	57,875	68,769	N/A
6/30/2022	157,251	50,539	57,680	66,037	N/A
3/31/2022	149,027	49,344	59,665	67,331	N/A
12/31/2021	140,800	47,757	47,615	55,000	N/A
9/30/2021	134,605	46,183	40,213	58,189	N/A
6/30/2021	129,910	44,362	31,814	54,188	N/A
3/31/2021	126,875	42,864	31,337	53,194	N/A
12/31/2020	126,946	42,138	29,870	51,951	N/A
9/30/2020	127,225	41,537	44,800	56,944	N/A
6/30/2020	126,575	41,433	47,621	56,126	N/A
3/31/2020	126,605	40,403	36,987	46,904	N/A
12/31/2019	122,021	38,951	35,551	46,782	N/A
9/30/2019	119,336	38,731	36,785	49,029	N/A
6/30/2019	116,821	37,574	31,251	43,960	N/A
3/31/2019	114,192	38,322	32,202	44,691	N/A
12/31/2018	111,831	38,628	32,206	44,616	N/A
9/30/2018	110,091	38,384	31,576	43,236	N/A
6/30/2018	108,943	39,117	33,787	44,538	N/A
3/31/2018	110,174	38,725	28,991	38,885	N/A
12/31/2017	111,696	38,130	N/A	41,168	N/A
9/30/2017	113,276	38,576	N/A	46,289	N/A
6/30/2017	114,199	38,609	N/A	48,557	N/A
3/31/2017	113,020	38,626	N/A	52,937	N/A
12/31/2016	111,780	37,925	N/A	48,314	N/A
9/30/2016	111,084	37,484	N/A	47,280	N/A
6/30/2016	110,339	36,064	N/A	44,179	N/A
3/31/2016	109,939	34,439	N/A	41,656	N/A
12/31/2015	107,927	34,860	N/A	38,287	N/A
9/30/2015	103,636	33,131	N/A	35,469	N/A
6/30/2015	99,093	31,248	N/A	35,578	N/A
3/31/2015	93,663	29,899	N/A	31,729	N/A
12/31/2014	88,806	26,481	N/A	31,692	N/A
9/30/2014	85,919	26,005	N/A	29,763	N/A
6/30/2014	84,181	25,920	N/A	23,783	N/A
3/31/2014	83,932	25,660	N/A	22,941	N/A
12/31/2013	83,572	25,184	N/A	25,942	N/A
9/30/2013	82,836	24,886	N/A	22,084	N/A
6/30/2013	82,170	24,138	N/A	23,829	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NOVO B's forecast earnings growth (13.3% per year) is above the savings rate (0.9%).

Earnings vs Market: NOVO B's earnings (13.3% per year) are forecast to grow faster than the Danish market (13.1% per year).

High Growth Earnings: NOVO B's earnings are forecast to grow, but not significantly.

Revenue vs Market: NOVO B's revenue (13.8% per year) is forecast to grow faster than the Danish market (11.3% per year).

High Growth Revenue: NOVO B's revenue (13.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NOVO B's Return on Equity is forecast to be very high in 3 years time (85.6%).

Novo Nordisk Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

Price target increased by 14% to kr.887

Novo Nordisk Revises Earnings Guidance for the Year 2023

Price target increased by 7.6% to kr.672

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Recent updates

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Key Executive recently sold kr.50m worth of stock

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Final dividend of kr.6.40 announced

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Price target increased by 14% to kr.887

President recently sold kr.145m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Insider recently sold kr.10m worth of stock

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Price target increased by 7.6% to kr.672

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies